Please use this identifier to cite or link to this item: http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/320
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAdvani, Anjali S.-
dc.date.accessioned2015-11-30T02:58:24Z-
dc.date.available2015-11-30T02:58:24Z-
dc.date.issued2013-
dc.identifier.urihttp://220.231.117.85:8000/handle/DHKTYTHD_123/320-
dc.description.abstractThe prognosis of adult acute lymphoblastic leukemia (ALL) remains poor and novel treatment strategies are needed. Antibody-based therapies represent such an approach. ALL cells express various surface antigens that are targets for monoclonal antibodies. This review focuses on 4 major classes of antibody therapy: (1) naked antibodies, (2) T-cell-engaging bispecific single-chain antibodies, (3) immunoconjugates/immunotoxins, and (4) chimeric antigen receptors. Preclinical and clinical data are reviewed. This area of research represents an exciting new approach to help improve the outcome of this disease. Several clinical trials are currently incorporating this therapy in the treatment of newly diagnosed and relapsed adult ALL patients.vi
dc.language.isoenvi
dc.publisherAmerican Society of Hematologyvi
dc.titleNew immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptorsvi
dc.typeArticlevi
Appears in CollectionsHuyết học = Hematology

Files in This Item:
File Description SizeFormat 
Hematology-2013-Advani-131-7.pdf
  Restricted Access
108.91 kBAdobe PDFThumbnail
Download Request Item


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.